Chinese inhibitor drug candidate becomes first to enter phase
Release time：2024-05-22 10:16:55 Source：Global Grid news portal
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
- Previous：Scheffler back to work at Colonial and Stricker returns to Senior PGA in Michigan
- Next：Tennessee latest state to mandate automatic defibrillators at high schools
Related articles
- Progressive prosecutor in Portland, Oregon, seeks to fend off tough
- José Ramírez gets key hit to help the Guardians beat the Red Sox 10
- MAN UNITED CONFIDENTIAL: How more than TEN stars could be exit
- Russia begins withdrawing peacekeeping forces from Karabakh, now under full Azerbaijan control
- Politically motivated crimes in Germany reached their highest level in 2023 since tracking began
- The United States and China are expected to win the most medals at the Paris Olympics
- China's low
- 3 Vietnamese land rights protesters released early from prison — Radio Free Asia
- Warner holds out IPL hot shot Fraser
- Massachusetts official warns AI systems subject to consumer protection, anti
- Kansas takes control in the ninth and beats Kansas State in the opener of the Big 12 Tournament
- The wild TRUTH behind 'Mormon face': Former member of ultra
- Chinese economy sustains recovery momentum, makes notable progress in Q1
- The United States and China are expected to win the most medals at the Paris Olympics
- Report says China is accelerating the forced urbanization of rural Tibetans
- Amed Rosario's RBI infield single in the 13th inning lifts the Rays to a 7
- UN report points to yawning gap of inequality in sexual and reproductive health worldwide
- Who will win the NHL's top awards this season? Here are AP's predictions
- Election 2024: Biden and the Democrats raised far less in April than Trump and the GOP
- Lululemon partners with Team Canada after Nike was called out for Team USA kits ahead of Paris 2024
Random recommendation
- Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Global Grid news portal sitemap